Chemomab Therapeutics (CMMB) Profit After Tax (2017 - 2025)

Chemomab Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at $1.9 million for Q4 2025.

• Quarterly Profit After Tax fell 36.79% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.0 million (down 35.5% YoY) and the FY2025 annual result came in at -$9.0 million, up 35.5% from the prior year.
• Profit After Tax was $1.9 million for Q4 2025 at Chemomab Therapeutics, up from $1.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at $8.8 million in Q1 2023 and bottomed at -$47.0 million in Q4 2022.
• A 5-year average of -$2.6 million and a median of $2.5 million in 2024 frame the typical range for Profit After Tax.
• Peak annual rise in Profit After Tax reached 372.24% in 2022, while the deepest fall reached 833.68% in 2022.
• Chemomab Therapeutics' Profit After Tax stood at -$5.0 million in 2021, then plunged by 833.68% to -$47.0 million in 2022, then rose by 4.24% to -$45.0 million in 2023, then soared by 106.58% to $3.0 million in 2024, then slumped by 36.79% to $1.9 million in 2025.
• Business Quant data shows CMMB's Profit After Tax at $1.9 million in Q4 2025, $1.7 million in Q3 2025, and $2.1 million in Q2 2025.